GNTW yields 66.67% · ABBV yields 3.06%● Live data
📍 GNTW pulled ahead of the other in Year 1
Combined, GNTW + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GNTW + ABBV for your $10,000?
Stemtech Corporation, a stem cell nutrition company, develops and sells various dietary supplements. It offers stemrelease3, a stem cell enhancer, which supports the body's natural renewal system, a general sense of wellbeing, and telomeres health, as well as promotes youthful and healthy aging; StemFlo that supports optimal blood and healthy stem cell flow, protect the cardiovascular system from oxidative damage, boosts vitality, and promotes healthy aging; and MigraStem, a natural source of potent antioxidants, phytonutrients, fiber, and polysaccharides, which optimizes the migration of stem cells, enhance the immune system performance, support detoxification and anti-oxidative functions, enhances healthy longevity, and provide vitality and well-being. The company also provides OraStem that protects, strengthens, rejuvenates, restores, and supports teeth and gum function from the cellular level, as well as offer anti-oxidative and anti-microbial protection, supports tooth strength with essential minerals, helps to remove stains, brightens teeth in a natural and non-abrasive way, and freshens breath; and D-Fuze, an electromagnetic frequency (EMF) filter that protects the body from potential harm by dispersing EMFs to lower the specific absorption rate. It serves customers in Australia, Canada, Ecuador, Malaysia, Mexico, Namibia, New Zealand, the Philippines, Singapore, South Africa, Taiwan, Togo, and the United States. The company was founded in 2005 and is based in Miramar, Florida.
Full GNTW Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.